Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro by Kuittinen, Tea et al.
Abstract. Background/Aim: Endometrial cancer cells are
known to be sensitive to carboplatin and paclitaxel.
Furthermore, vitamin D (1,25-D3) has been reported to inhibit
endometrial cancer cell growth both as a single agent and
combined with carboplatin. However, there are no studies
comparing the effect of paclitaxel and carboplatin as single
agents vs. in combination in endometrial cancer cell lines.
Neither has the effect of 1,25-D3 been studied with paclitaxel.
The present study investigated the effect of paclitaxel,
carboplatin and 1,25-D3 on the growth of endometrial cancer
cells in vitro. Materials and Methods: Two endometrial
adenocarcinoma cell lines (UT-EC-1 and UT-EC-3) were
cultured with different doses of paclitaxel, carboplatin and
1,25-D3. The cellular VDR (vitamin D receptor) mRNA levels
were measured and the expression of estrogen (ER) and
progesterone (PR) receptors by the cells was determined.
Results: In the UT-EC-1 cell line the growth inhibition was
72% with paclitaxel, 54% with carboplatin and 73% with the
combination of these compounds. The corresponding numbers
in UT-EC-3 were 70%, 33% and 65%, respectively. 1,25-D3
suppressed cell growth 88% with paclitaxel, 63% with
carboplatin and 87% with their combination in the UT-EC-1
cell line. Conclusion: In both cell lines, single-agent paclitaxel
was as effective as the combination of the compounds and
more effective than single carboplatin. 1,25-D3 may further
contribute to the cytotoxic effect of these agents.
Endometrial cancer is the most common gynecological
malignancy in developed countries. In Finland incidence is
13.9 per 100,000 persons a year (1). Most women are
diagnosed with early-stage disease and have a high cure rate
with surgery alone with a reported 5-year survival rate of
90% (2). Still up to 25% of women will have advanced, high
grade or recurrent disease and require additional treatment.
In these cases, the therapeutic response to cytotoxic and
hormonal agents has been typically only partial and of short
duration. There is no generally accepted standard
chemotherapy in treatment of advanced and recurrent
endometrial carcinoma but simultaneous administration of
carboplatin and paclitaxel or carboplatin and pegylated
liposomal doxorubicin are widely used (3-8). 
Vitamin D is an antiproliferative and immunomodulatory
secosteroid hormone with a well-established role in
maintenance of calcium synthesis. Active metabolite of
vitamin D, 1alpha,25-dihydroxyvitamin D3 (1,25-D3) binds
to the vitamin D receptor (VDR) in the cell nucleus. The
function and/or expression of the VDR is needed for the
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growth regulatory effects of 1,25-D3 in vitro and disabled
VDR activity leads to 1,25-D3 insensitivity and accelerated
tumorigenesis (9). Many different cell types, including
normal and malignant endometrial cells, contain VDR and
1alpha hydroxylases to synthesize active 1,25-D3 locally (10,
11). This active metabolite does not enter the circulation and
has no effect on calcium homeostasis, but is rather degraded
by 24-hydroxylases.
1,25-D3 is well known for its antiproliferative roles
including the induction of G0-G1 cell-cycle arrest with
associated down-regulation of oncogenic cyclins D1 and D3
and p27/p21 induction (12-15). 1,25-D3 is responsible for
VDR-mediated apoptosis and inhibits angiogenesis and
differentiation in a variety of cancer types (13, 16-20). 1,25-
D3 is a potential antitumor agent because of its ability to
regulate cancer cell growth. 1,25-D3 has been found to
inhibit endometrial cancer cell growth both as a single agent
(21) and combined with carboplatin (22).  
Endometrial cancer cells are sensitive to carboplatin,
cisplatin and paclitaxel (23, 24). Still there are no studies
comparing paclitaxel and carboplatin as single agents vs. in
combination in endometrial cancer in vitro or in vivo. In
addition, there are no studies examining the effect of vitamin
D with paclitaxel or the combination of paclitaxel and
carboplatin on endometrial cancer cells. The aim of the
present study was to investigate the potential effects of
paclitaxel, carboplatin and 1,25-D3 on the growth of
endometrial cancer cells both as single agents and in
different combinations with each other in vitro.
Materials and Methods
Cell lines. Two endometrial adenocarcinoma cell lines were used
(UT-EC-1 and UT-EC-3) in this study. The cell lines were originally
established from primary tumors before any treatment using an
explant technique (25, 26). UT-EC-1 was established from a
curettage specimen of a clinical FIGO Stage II Grade 2 endometrial
papillary adenocarcinoma and UT-EC-3 from the hysterectomy
specimen of a surgical FIGO Stage Ia Grade 3 endometrial
adenocarcinoma (23). The biological properties of these cell lines
have been described in detail earlier (23).
Cell cultures and treatments. Prior to the experiments the cells were
cultured as described previously (23). In brief, the cells were plated
weekly and maintained in logarithmic phase in 75 cm2 culture flasks
in Dulbecco’s modified Eagle minimal essential medium (DMEM),
supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin, 1% glutamine and 1% non-essential amino
acids at 37ºC in a humidified atmosphere containing 5% CO2. Both
cell lines were tested negative for mycoplasma contamination.
Paclitaxel (Hospira® 6 mg/ml, Maidenhead, UK) and carboplatin
(Accord® 10 mg/ml, Middlesex, UK) were provided by the
Pharmacy of the Tampere University Hospital. 1,25-D3 was
purchased from Sigma-Aldrich (St. Louis, MO, USA). Paclitaxel was
diluted in 0.9% sodium chloride to get a 0.1 mM solution. Stock
solutions of 100 nM were made in DMEM. Final concentrations
used were 1-100 nM and fresh stock solutions were made for each
experiment. Carboplatin was diluted in sterile water to get a solution
of 100 μg/ml. The final dilutions used were 0.1-20 μg/ml. The
dilutions were made immediately before use. 1,25-D3 was diluted in
DMEM to get final 0.1-100 nM solutions. The concentrations of
drugs were based on previous reports as well as physiological
relevance (23, 24, 27, 28).
VDR, ER and PR expression analyses. The VDR mRNA levels in UT-
EC-1 and UT-EC-3 cells were measured by qRT–PCR using the
LightCycler equipment (Roche, Mannheim, Germany). Total RNA
was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA,
USA) and was reverse transcribed with SuperScript™ First-Strand
Synthesis System for RT–PCR (Invitrogen, Carlsbad, CA, USA) as
described (29). qRT-PCR was performed using 20 μM gene specific
primers (Sigma-Aldrich, sense 5’ ATCGGCATGATGAAGGAGTT
3’, antisense 5’ TGCTCCTCAGACAGCTTGG 3’) and 10 μM UPL
probe (probe number # 12). The PCR program included the following
steps: 10 min denaturation at 95˚C followed by 45 cycles of 10 s
denaturation at 95˚C, 30 s annealing at 60˚C and 1 s elongation at
72˚C. The expression levels were normalized using glyceraldehyde-
3-phosphate dehydrogenase (GAPD) housekeeping gene. 
The expression of estrogen (ER) and progesterone (PR) receptors
in both cell lines was determined with immunohistochemical
staining. ER and PR immunostainings were performed using
Ventana Benchmark Ultra automated IHC/ISH Slide staining system
(Ventana Medical Systems, AZ, USA). Deparaffinization and
antigen retrieval were performed using Roche Ventana reagents (EZ
Prep 10X concentrate and Cell Conditioning Solution CC1). ER
staining was performed using a Roche Ventana RTU Confirm anti-
Estrogen Receptor Rabbit monoclonal antibody (Clone SP1) with
32 min incubation time. PR staining was performed using a Roche
Ventana RTU Confirm anti-Progesterone Receptor Rabbit
monoclonal antibody (Clone 1E2) with 24 min incubation time.
Both immunostainings were detected and visualized using Roche
Ventana UltraView DAB IHC Detection Kit. 
Cell growth assays. For each experiment, the cells were plated on
24-well plates at 30,000 cells/well. Cells were then treated with
indicated doses of paclitaxel (1-100 nM), carboplatin (0.1-20 μg/ml)
and vitamin D3 (0.1-100 nM) alone or in combination. After a 3-
day incubation period, the cells were trypsinized and counted using
the Z2 Coulter Counter (Beckman Coulter, Fullerton, CA). All
experiments were done in six replicates and were repeated at least
twice. 
Statistical analyses. Non-parametrical Mann-Whitney test was used to
assess differences between treated and control groups. Exact p-values
under 0.05 were considered as statistically significant. All statistical
analyses were performed using IBM SPSS Statistics version 23 (IBM
SPSS Statistics, IBM Corporation, Chicago, IL).
Results
The cells were first cultured with different concentrations of
paclitaxel (1, 3, 5, 10, 50, and 100 nM) and carboplatin (0.1
μg/ml, 0.5 μg/ml, 5 μg/ml, 10 μg/ml, and 20 μg/ml) to
obtain the estimated drug concentration causing at least 50%
inhibition of cancer cell growth (IC50). In UT-EC-1 cell line
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the concentration of carboplatin was set in between 0.5-1
μg/ml and the one of paclitaxel was 5 nM. In UT-EC-3 the
IC50 was 0.1-1 μg/ml for carboplatin and 1-5 nM for
paclitaxel, respectively. A decision was made to use the
same concentrations for the both cell lines because the
estimated values were so close to each other, 3 nM for
paclitaxel and 0.5 μg/ml for carboplatin. Thus, both cell
lines were treated either with 3 nM paclitaxel, 0.5 μg/ml
carboplatin or with a combination of the two agents and cell
growth was compared to untreated controls. In UT-EC-1 cell
line growth inhibition with paclitaxel was 72%, with
carboplatin 54% and with combination 73%. In UT-EC-3
cell line growth inhibition was 70% with paclitaxel, 33%
with carboplatin and 65% with paclitaxel and carboplatin
together (Figure 1). In both cell lines, single agent paclitaxel
was as effective as the combination of the drugs and more
effective than single agent carboplatin. In other words, no
additive or synergistic effect was achieved by using them
combined with each other. The difference was significant
when comparing the effect of single paclitaxel to single
carboplatin in both cell lines (p=0.002). There was no
statistical significance in either one of the cell lines when
comparing single paclitaxel to the combination of the
paclitaxel and carboplatin (p=0.240). 
In the second part of the study UT-EC-1 and UT-EC-3 cells
were treated with the different concentrations of 1,25-D3 (0.1,
1, 10, 50, and 100 nM) to determine its effect on the growth
of the cell lines. There was no growth inhibition with 1,25-
D3 in UT-EC-3 cells (Figure 2). In UT-EC-1 cells there was
a 24% (p=0.002) and 32% (p=0.009) growth inhibition with
50 nM and 100 nM doses of 1,25-D3 as compared to the
control, respectively (Figure 2). The vitamin D receptor
(VDR) expression status was further examined in both cell
lines. The UT-EC-1 cells expressed VDR whereas UT-EC-3
did not (Figure 3). Regarding the ER/PR expression, both cell
lines were found to be ER- and PR-negative. 
The VDR-positive UT-EC-1 cell line was selected for the
subsequent experiment. The 50 nM dose of 1,25-D3 was
chosen because it is closer to the physiological and clinically
attainable concentrations. The cells were cultured with i) 3
nM paclitaxel and 50 nM 1,25-D3, ii) 0.5 μg/ml carboplatin
and 50 nM 1,25-D3 and iii) 3 nM paclitaxel, 0.5 μg/ml
carboplatin and 50 nM 1,25-D3. Cells were counted as
described previously and growth inhibition was analyzed
relative to untreated control cells. Paclitaxel and 1,25-D3
suppressed cell growth 88%, carboplatin and 1,25-D3 63%
and paclitaxel, carboplatin and 1,25-D3 87% in comparison
to the control (Figure 4). Single-agent paclitaxel combined
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Figure 1. Effect of cytotoxic agents on UT-EC-1 and UT-EC-3 endometrial adenocarcinoma cells growth. The cells were treated for three days with
indicated drugs and cell numbers were determined. Mean and SD of six replicates are shown.
with 1,25-D3 were as effective as the combination of all
three (p=0.002) and more effective than single agent
carboplatin combined with 1,25-D3 (p=0.002). 
Discussion
In the present study we tested the effects of paclitaxel and
carboplatin as single agents and in combination with and
without 1,25-D3 on the growth of endometrial cancer in vitro.
Our results suggest that paclitaxel alone is as effective as the
combination of paclitaxel and carboplatin and more effective
than carboplatin alone in inhibiting the growth of endometrial
cancer cells. Our data also imply that combining 1,25-D3 with
paclitaxel and carboplatin, may further potentiate the growth
inhibition of the cancer cells. The additive effect of 1,25-D3 was
17%, 15% and 16% when compared to single-agent paclitaxel,
single agent carboplatin and paclitaxel and carboplatin in
combination, respectively. On the other hand, adding
carboplatin did not provide any additive or synergistic effect, as
compared to the combination of paclitaxel and 1,25-D3. 
The authors are not aware of any studies comparing
clinically single-agent carboplatin and paclitaxel with their
combination in endometrial cancer. In phase II studies, the
response rate of advanced or recurrent chemo-naïve
endometrial cancer to both drugs has been in the order of
35% (30, 31). Hoekstra et al. (32) compared cytoreductive
ability of carboplatin and paclitaxel on endometrial
ANTICANCER RESEARCH 37: 6575-6581 (2017)
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Figure 2. Effect of various concentrations of 1,25-D3 on UT-EC-1 and UT-EC-3 endometrial adenocarcinoma cells growth. The cells were treated
for three days with indicated concentrations of 1,25-D3 and cell numbers were determined. Mean and SD of six replicates are shown.
Figure 3. VDR expression in UT-EC-1 and UT-EC-3 endometrial
adenocarcinoma cell lines.
carcinoma cells. A concentration of 10 nM paclitaxel induced
over 90% cell death in 24 h whereas that induced by
carboplatin was only 30-40%. This is in line with our results,
the cytoreduction rate of paclitaxel was 25% higher in 
UT-EC-1 cell line and 53% higher in UT-EC-3 cell line than
that of carboplatin. 
Ballard et al. (33) evaluated micro-culture kinetic (MiCK)
apoptosis assay to predict response of endometrial cancer
cells in vitro to single or combination chemotherapy. The
results were compared to previous GOG trials. They
collected 15 endometrial cancer specimens from total
abdominal hysterectomies. All grades, stages and histological
types were included. The study demonstrated that 25% of
patients might be treated with single-agent chemotherapy.
Paclitaxel, ifosfamide and cisplatin had high activity as
single agents of which paclitaxel had the highest activity.
The correlation of the mean kinetic units with the overall
response rates of GOG trials was also high. Single agent
paclitaxel appeared to show almost the same activity as the
combination of paclitaxel and carboplatin (3.1 vs. 3.4). This
is in concordance with our results. The present and previous
results imply that it may be reasonable to design at least a
randomized Phase II study comparing paclitaxel alone to the
combination of paclitaxel and carboplatin in advanced/
recurrent endometrial cancer.
Our preliminary results show that 1,25-D3 may have an
additive inhibitory effect with cytotoxic agents in
endometrial cancer cells expressing VDR. Paclitaxel and
1,25-D3 had a growth inhibitory effect of 88% compared to
72% of single paclitaxel. A potential bias of the present study
is the fact that the experiments were done partly separately.
However, we used non-commercial well-established cell
lines, and a synergistic anti-tumor effect was seen in UT-EC-
1 cell line also with carboplatin and 1,25-D3 (63% vs. 54%),
as well as with the combination of all three (87% vs. 73%).
Of note is that the 1,25-D3 sensitive UT-EC-1 cell line
expressed strongly VDR, while UT-EC-3 did not. Taking the
low toxicity of vitamin D into account, it would be
interesting to test this phenomenon also clinically.
Earlier studies support the present findings. Saunders et
al. (22) found additive inhibition of endometrial carcinoma
cell growth by carboplatin and calcitriol. Lee et al. (17)
studied anti-tumor effects of progesterone and 1,25-D3 in
endometrial cancer cell lines and immortalized human
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Figure 4. Cell growth inhibition in UT-EC-1 endometrial adenocarcinoma cells with different combinations of cytotoxic agents and 1,25-D3. The
cells were treated for three days with indicated drugs and cell numbers were determined. Mean and SD of six replicates are shown.
endometrial epithelial cells. They found that both agents
enhanced vitamin D receptor expression and inhibited cell
proliferation through caspase-3 activation. Yabushita et al.
(21) examined the localization of vitamin D receptor
immunohistochemically in 21 endometrial adenocarcinoma
specimens, and the effect of 1,25(OH)2D3 on cell growth.
The VDR was detected in 14 of the 21 specimens. They
cultured one cell line expressing VDR with 50 nM
1,25(OH)2D3, resulting in 44% growth inhibition. In
contrast, the cells not expressing VDR were completely
uninhibited when cultured with 100 nm 1,25-D3 which is in
concordance with our results. According to these findings,
endometrial adenocarcinoma is a potential target of 1,25-D3.
VDR-negative breast cancer has been found to relapse
earlier than VDR-positive one (34). LaPorta et al. (35)
reported that 1,25-D3 down-regulates four genes that are
known to promote tumorigenesis in breast cancer cells. It has
been also demonstrated that the highest expression of VDR,
ER and androgen receptors was related to the best prognosis
(36). Further, VDR-agonists have been shown to have
growth inhibitory effect in established human breast cancer
xenografts in animal models (37). 1,25-D3 has been found
to be a potential antiproliferative agent but dose-limiting
calcemic effects have been noticed as a major obstacle (37). 
Peng et al. (38) reported that estrogen receptor-positive
breast cancer cells were sensitive whereas estrogen receptor-
negative ones were resistant to the antiproliferative effects
of vitamin D and its analogs. Furthermore they found that
intact VDR-signaling machinery in the cell nucleus is
essential for this action. In our study both cell lines were
estrogen and progesterone receptor-negative. However, the
VDR-positive UT-EC-1 cell line responded to the growth
inhibitory effect with 1,25-D3. The different VDR status in
the cell lines might be due to differences in VDR-signaling
machinery and local production and deactivation of the 1,25-
D3. On the other hand, it seems that in ovarian cancer,
expression of VDR is independently regulated from the
expression of estrogen and progesterone receptors (39).
Whether this also takes place in endometrial cancer cells
remains to be elucidated. 
In conclusion, we demonstrated with two endometrial
carcinoma cell lines that paclitaxel alone seems to be as
effective as the combination of carboplatin and paclitaxel in
vitro. In addition, 1,25-D3 had a growth-inhibitory effect on
the VDR expressing cell line both alone and combined with
paclitaxel and carboplatin. 
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